Pathology Monitoring Articles & Analysis: Older
4 news found
About DiamiR DiamiR is a privately held molecular diagnostics company focused on developing minimally invasive tests for detection and monitoring of pathology based on quantitative analysis of organ-enriched microRNA signatures in plasma for screening, patient stratification, as well as disease progression and treatment monitoring. ...
ByDiamiR
Patent Application No. 16/044,279 entitled "miRNA-based methods for detecting and monitoring aging." The patent covers the use of methods developed by DiamiR based on targeted quantitative analysis of microRNAs enriched in the brain and detectable in blood plasma as biomarkers of brain aging. ...
ByDiamiR
With research efforts, such as DiamiR's epigenetics-based blood tests, we aim to accelerate the development of these tools so we can more easily and specifically screen and diagnose patients, stage disease progression, monitor response to treatment, and improve the rigor and efficiency of clinical trials." ...
ByDiamiR
"AD is proving to be an extremely difficult indication to develop treatment for due to its heterogeneity and not well understood causes of the pathology associated with the disease. Accurate, minimally-invasive biomarkers reflective of underlying pathophysiological processes are urgently needed," said Samuil Umansky, MD, PhD, CSO of DiamiR and Principal Investigator on the ...
ByDiamiR